Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection of our formulations facility located at Sanand, Ahmedabad, ....
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals disclosed that the US FDA conducted a cGMP inspection at its formulations facility in Sanand, Ahmedabad from May 6 to May 15, 2026. The regulatory authority issued a Form 483 with 7 observations, which the company described as procedural in nature. Emcure stated it is comprehensively addressing the observations and will respond to the US FDA within the stipulated timeframe. This disclosure was made under SEBI Regulation 30 as a material event.
Form 483 observations, though described as procedural, carry reputational and operational risk. Investors may watch for resolution timelines, as unresolved observations could potentially impact US market revenues for the company.